BioVie to Present Positive Bezisterim Data for Parkinson's Disease at International Conference
BioVie Inc., a clinical-stage biopharmaceutical company, is scheduled to present new data on its investigational drug, bezisterim (NE3107), at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases in Barcelona, Spain, from March 16-20, 2027. The presentations will focus on exploratory analyses from the Phase 2 SUNRISE-PD trial, which evaluated bezisterim in 57 patients with early-stage Parkinson's disease. The study found that patients with higher systemic inflammation at baseline, defined by platelet counts above 230 × 10^9/L, showed significant improvements in both motor and non-motor symptoms of Parkinson's disease. Specifically, this subgroup experienced better scores in the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I (non-motor), Part III (motor), and Total Scores. The drug works by modulating key pathways involved in neuroinflammation and improving insulin sensitivity without suppressing the immune system.
